ROR1 and B-cell chronic lymphocytic leukemia: In particular, T cells isolated from patients receiving ibrutinib for longer than 6 months and co-cultured with autologous CLL cells and anti-ROR1 BiTE demonstrated an enhanced cytotoxicity compared to T cells from non-ibrutinib treated patients (66).